Beractant inj

Beractant inj
Trade name
Drug class
Presentation
Cost
Prescriber
Indication
Dose
Location
Administration
Stability / expiry
Compatibility
Incompatibility
Survanta
Pulmonary surfactant
Single-use glass vial containing 200mg/8ml off-white to light brown suspension.
RM1,260.00 per 8mL vial
Paediatric specialist (SCN)
Prevention and treatment (rescue) of Respiratory Distress Syndrome (RDS) in
premature infants.
100mg of phospholipids/kg birth weight (4ml/kg). Four doses can be administered
in the first 48 hours of life, given no more frequently than every 6 hours.
Prevention: Give as soon as possible, preferably within 15 minutes of birth.
Treatment: Give as soon as possible, preferably by 8 hours of age.
Cawangan PharmUMMC
IM injection: NA
SC injection: NA
IV injection: NA
IV infusion: NA
Intrathecal: Administered through a 5 French end-hole catheter inserted into the
infant’s endotracheal tube with the tip of catheter protruding just beyond the end of
the endotracheal tube above the infant’s carina. Should not be instilled into the main
stem bronchus. Before administration, beractant should be warmed by standing at
room temperature for at least 20 mins or warmed in the hand for at least 8 mins.
Intraperitoneal: NA
Reconstituted solution: NA
Undiluted solution: Store unopened vials at 2-8°C. Protect from light. Store vials
in carton until ready for use. Upon opening, discard unused drug.
Compatible fluids: D5W, D10W, NS, Hartmann’s. Compatible with whole blood,
plasma and other blood products
Compatible drugs: NA
Compatible via Y site: NA
Compatible in syringe: No information
Incompatible fluids: Avoid mixing with protein hydrolysates or amino acid
solutions, solutions with alcohol, or solutions of drugs which bind to albumin (e.g.
phenytoin, diazepam, calcium channel blockers, chlorpromazine). WFI may
substantially reduce tonicity.
Incompatible drugs: NA

Special precautions • For IT use only
Special notes
Patient information
Prepared/checked by
Date compiled/edition
• If settling occurs during storage, swirl the vial gently to redisperse (DO NOT
SHAKE)
• Does not require reconstitution or sonication before use.
• Unopened, unused vials that have been warmed to room temperature may be
returned to the refrigerator within 8 hrs of warming and stored for future use.
Drug should not be warmed and returned to the refrigerator more than once.
• Can rapidly affect oxygenation and lung compliance, therefore should be used
under supervised clinical setting.
• Rales and moist breath sounds can occur transiently after administration.
• Increased probability of post-treatment nosocomial sepsis in Survanta ® treated
infants.
• Use in infants 1750g birth weight has not been
evaluated in controlled trials.
4 vials are stocked in SCN.
Parents are to replace stock used by purchasing from Cawangan PharmUMMC
Borang Ubat Khas form is required to be completed if parent is unable to pay cost of
drug. Replacement vials are given to SCN when the form is received together with
the prescription.
Adverse reactions include transient bradycardia, oxygen desaturation
Tan Siau Ying / PDS / HKD / PL
9 Jan 2010, 1 st edition